MYB and acute myeloid leukemia: Targeting Myb with small-molecule inhibitors therefore offers potential for the development of novel therapeutic strategies for the treatment of AML and other tumors with deregulated Myb, such as adenoid cystic carcinoma or specific subtypes of glioblastoma [12,13].